Targeting Non-coding RNA Sensitizes Cancer Cells to Drugs.
Recently, Costales and colleagues (J. Am. Chem. Soc. 2019;141:2960-2974) reported a bivalent small molecule inhibitor of primary miRNA (pri-miR)-515. Perturbation of pri-miR-515 results in the upregulation of HER2 protein levels, rendering HER2- breast cancer cells more sensitive to Herceptin treatment. This strategy represents a novel pharmacological approach to selectively modulating disease-relevant proteins in tumor cells.